[1] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world [J]. J Clin Oncol, 2006, 24(14):2137-2150 [2] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. Ca Cancer J Clin, 2014, 64(1):9-29 [3] Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review [J]. EMBO Mol Med, 2012, 4(3):143-159 [4] Ghosh RD, Ghuwalewala S, Das P, et al. MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features [J]. Sci Rep, 2016, 6:23932 [5] Dai Y, Xie CH, Neis JP, et al. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance [J]. Head Neck, 2011, 33(6):786-791 [6] Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm [J]. Nat Rev Cancer, 2013, 13(10):714-726 [7] Lu S, Yu L, Mu Y, et al. Role and mechanism of Twist1 in modulating the chemosensitivity of FaDu cells [J]. Mol Med Rep, 2014, 10(1):53-60 [8] Yu J, Xie F, Bao X, et al. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer [J]. Mol Cancer, 2014, 13:121 [9] Peng F, Zhang H, Du Y, et al. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist [J]. Oncol Rep, 2015, 33(2):942-950 [10] Zhao L, Ren Y, Tang H, et al. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential [J]. Oncotarget, 2015, 6(42):44538-44550 [11] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future [J]. Annu Rev Pharmacol Toxicol, 2014, 54:95-117 [12] Gao M, Miao L, Liu M, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1 [J]. Oncotarget ,2016,7(37):59714-59726 [13] Wang W, Songlin P, Sun Y, et al. miR-21 inhibitor sensitizes human OSCC cells to cisplatin [J]. Mol Biol Rep, 2012,39(5):5481-5485 [14] Ren W, Wang X, Gao L,et al. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4 [J]. Mol Cell Biochem, 2014,390(1-2):253-262 [15] Suen DF, Norris KL, Youle RJ.Mitochondrial dynamics and apoptosis [J]. Genes Dev, 2008, 22(12):1577-1590 [16] Fan S, Chen WX, Lv XB, et al. miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1 [J]. Cancer Lett, 2015,362 (2):183-191 [17] Fan S, Liu B, Sun L, et al. Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis [J]. Oncotarget,2015,6(17):14885-14904 [18] Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance [J]. Drug Resist Updat, 2010, 13(4-5):109-118 [19] Wu B, Lei D, Wang L, et al. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1 [J]. Am J Cancer Res,2016,6(6):1396-1407 [20] Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells [J]. J Pathol ,2011, 223(4):482-495 [21] Xia H, Cheung WK, Sze J, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling [J]. J Biol Chem, 2010, 285(47):36995-37004 [22] Yu CC, Chen YW, Chiou GY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation [J]. Oral Oncol, 2011, 47(3):202-210 [23] Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer [J]. J Clin Oncol, 2007, 25(16):2164-2170 [24] Lin C, Lu W, Ren Z, et al. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma [J]. Cancer Lett, 2016, 377(1):1-10 [25] Sui C, Xu F, Shen W, et al. Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET [J]. Tumour Biol, 2015, 36(3):1511-1518 [26] Tian H, Gao Z, Li H, et al. DNA damage response--a double-edged sword in cancer prevention and cancer therapy [J]. Cancer Lett, 2015, 358(1):8-16 [27] Li X, Li Y, Qiu LH, et al. Expression of excision repair cross-complementation gene in drug-resistant process of carboplatin administration in tongue squamous cell cancer (Tca8113) [J]. Chin J Stomatol, 2011,46(7):437-441 |